Stay updated on Intratumoral TAK-981 Microdosing in Head and Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Intratumoral TAK-981 Microdosing in Head and Neck Cancer Clinical Trial page.

Latest updates to the Intratumoral TAK-981 Microdosing in Head and Neck Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has been updated to reflect new information regarding the evaluation of TAK-981 in combination with cetuximab and avelumab for head and neck cancer, including the addition of collaborators and a revision update. The previous detailed description of the study's methodology has been removed.SummaryDifference34%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Intratumoral TAK-981 Microdosing in Head and Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Intratumoral TAK-981 Microdosing in Head and Neck Cancer Clinical Trial page.